Corcept officer exercises, sells 10,000 shares

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options for a total of 10,000 shares of common stock on September 14, 2026, at exercise prices of $11.35 and $13.56 per share, and sold 10,000 shares the same day in open-market or private transactions under a Rule 10b5-1 trading plan.

The sales were executed in two tranches at weighted average prices of $113.32 and $114.12 per share, and the filing notes that Lyon also holds unvested restricted stock awards scheduled to vest one year after their respective grant dates, subject to specified service conditions.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($1.01M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Lyon Joseph Douglas

Role See Remarks

Sold 10,000 shs ($1.13M)

Approx. gross sale proceeds $1.13M

Approx. exercise cost $130K

Approx. pre-tax spread $1.01M

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) F5	2,596	$0.00	$0.00
Exercise	Stock option (right to buy) F5	7,404	$0.00	$0.00
Exercise	Common Stock F1	2,596	$11.35	$29K
Exercise	Common Stock F1	7,404	$13.56	$100K
Sale	Common Stock F2, F3, F1	7,812	$113.3206	$885K
Sale	Common Stock F2, F4, F1	2,188	$114.1163	$250K

Holdings After Transaction: Stock option (right to buy) — 4,167 contracts (Direct); Common Stock — 5,683 shares (Direct)

Footnotes (5)

1. F1. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. F5. Fully exercisable.

Key Figures

Options exercised at $11.35: 2,596 shares Options exercised at $13.56: 7,404 shares Total options exercised: 10,000 shares +4 more

7 metrics

Options exercised at $11.35 2,596 shares Stock options exercised into common stock on September 14, 2026 at $11.35 per share

Options exercised at $13.56 7,404 shares Stock options exercised into common stock on September 14, 2026 at $13.56 per share

Total options exercised 10,000 shares Combined option exercises by the officer on September 14, 2026

Shares sold at $113.3206 7,812 shares Weighted average sale price range $112.81–$113.72 per share

Shares sold at $114.1163 2,188 shares Weighted average sale price range $113.92–$114.50 per share

Total shares sold 10,000 shares Aggregate common shares sold by the officer on September 14, 2026

Unvested restricted stock awards 1,243 shares Sum of unvested restricted stock awards (178, 398, 537, 130 shares) subject to one-year vesting from each grant date

Key Terms

Rule 10b5-1 plan, weighted average sale price, restricted stock awards

3 terms

Rule 10b5-1 plan regulatory

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold."

restricted stock awards financial

"Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CORT report for Joseph Douglas Lyon on September 14, 2026?

The officer exercised stock options for 10,000 shares of Corcept Therapeutics common stock and sold 10,000 shares on September 14, 2026, combining option exercises with same-day open-market or private sales.

At what prices were the Corcept Therapeutics (CORT) options exercised by the officer?

Joseph Douglas Lyon exercised options for 2,596 shares at $11.35 per share and 7,404 shares at $13.56 per share, each converting into an equivalent number of Corcept Therapeutics common shares on September 14, 2026.

At what prices did the Corcept Therapeutics (CORT) officer sell shares on September 14, 2026?

He sold 7,812 shares at a weighted average price of $113.3206 per share and 2,188 shares at a weighted average price of $114.1163 per share. The filing states actual prices ranged within narrow bands around each weighted average.

Were the September 14, 2026 CORT insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Joseph Douglas Lyon on June 10, 2026, which was in effect at the time of the trades.

How many Corcept Therapeutics (CORT) options did the officer exercise in total?

On September 14, 2026, Joseph Douglas Lyon exercised stock options covering 10,000 shares of Corcept Therapeutics common stock, consisting of 2,596 shares from one grant and 7,404 shares from another grant that were fully exercisable.

What unvested restricted stock awards does the Corcept Therapeutics (CORT) officer hold?

The filing notes unvested awards for 178 shares granted December 1, 2025, 398 shares granted March 2, 2026, 537 shares granted June 1, 2026, and 130 shares granted September 1, 2026, all vesting in full one year after each grant if service conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:31 PM Accepted by SEC EDGAR 09/16/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyon Joseph Douglas

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		M		2,596	A	$11.35	8,279(1)	D
Common Stock	09/14/2026		M		7,404	A	$13.56	15,683(1)	D
Common Stock	09/14/2026		S(2)		7,812	D	$113.3206(3)	7,871(1)	D
Common Stock	09/14/2026		S(2)		2,188	D	$114.1163(4)	5,683(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$11.35	09/14/2026		M			2,596	(5)	02/08/2029	Common Stock	2,596	$0.00	0	D
Stock option (right to buy)	$13.56	09/14/2026		M			7,404	(5)	02/07/2030	Common Stock	7,404	$0.00	4,167	D

Explanation of Responses:

1. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Fully exercisable.

Remarks:

Chief Accounting & Technology Officer

	/s/ Joseph Douglas Lyon	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)